Literature DB >> 29338895

Feasibility of total intravenous anesthesia by cardiologists with the support of anesthesiologists during catheter ablation of atrial fibrillation.

Takanori Yamaguchi1, Yusuke Shimakawa2, Shinji Mitsumizo3, Akira Fukui4, Yuki Kawano5, Toyokazu Otsubo4, Yuya Takahashi4, Kei Hirota4, Takeshi Tsuchiya4, Kenichi Eshima5.   

Abstract

BACKGROUND: The optimal methodology for sedation and anesthesia during atrial fibrillation (AF) ablation has not been well established. We assessed the feasibility of total intravenous anesthesia (TIVA) by cardiologists with support from anesthesiologists during AF ablation and quality of pulmonary vein isolation (PVI) and single procedure success rate at 12 months.
METHODS: TIVA was performed by cardiologists using IV propofol and fentanyl under controlled ventilation via i-gel™ without neuromuscular blocking drugs in 160 consecutive patients (80 nonparoxysmal) with no anticipated difficult airway or other severe diseases. Anesthesiologists were requested to be on standby during the procedure. The incidence of anesthesia-associated complications and ablation-associated complications were assessed. To evaluate the quality of PVI, the prevalence of acute adenosine triphosphate (ATP)-provoked PV reconnections and late PV reconnections among those requiring a redo procedure was analyzed.
RESULTS: TIVA was successfully completed in 152 patients (95%). In five (3%), we requested help from anesthesiologists, and in three (2%), TIVA was abandoned. No major anesthesia-associated complications were observed. Ablation-associated complications were observed in seven patients (4%). ATP provocation test was performed in 141 patients, and no acute PV reconnections were observed in 134 (95%). Success rates at 12 months were 85% of patients off antiarrhythmic drugs. Twenty-one of 24 patients with recurrence underwent a redo session, and 18 (86%) had no PV reconnections.
CONCLUSIONS: TIVA by cardiologists with support from anesthesiologists during AF ablation may be feasible. The success rate at 12 months was high, and prevalence of acute and late PV reconnection was very low.
Copyright © 2018 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Atrial fibrillation; Catheter ablation; General anesthesia; Pulmonary vein isolation; Total intravenous anesthesia

Mesh:

Substances:

Year:  2018        PMID: 29338895     DOI: 10.1016/j.jjcc.2017.12.008

Source DB:  PubMed          Journal:  J Cardiol        ISSN: 0914-5087            Impact factor:   3.159


  5 in total

1.  Prevalence and Factors Associated with Atrial Fibrillation Among Patients with Rheumatic Heart Disease.

Authors:  Sahadeb Prasad Dhungana; Rajesh Nepal; Rinku Ghimire
Journal:  J Atr Fibrillation       Date:  2019-12-31

2.  Avoiding Urinary Catheterization in Patients Undergoing Atrial Fibrillation Catheter Ablation.

Authors:  Andrew B Lehman; Asim S Ahmed; Parin J Patel
Journal:  J Atr Fibrillation       Date:  2019-12-31

3.  Laryngeal mask versus facemask in the respiratory management during catheter ablation.

Authors:  Takashi Koyama; Masanori Kobayashi; Tomohide Ichikawa; Yasushi Wakabayashi; Daiki Toma; Hidetoshi Abe
Journal:  BMC Anesthesiol       Date:  2020-01-07       Impact factor: 2.217

4.  Comparison of the Different Anesthesia Strategies for Atrial Fibrillation Catheter Ablation: A Systematic Review and Meta-Analysis.

Authors:  Naidong Pang; Jia Gao; Nan Zhang; Binghang Zhang; Rui Wang
Journal:  Cardiol Res Pract       Date:  2022-03-20       Impact factor: 1.866

5.  A comparison of clinical outcomes and cost of radiofrequency catheter ablation for atrial fibrillation with monitored anesthesia care versus general anesthesia.

Authors:  Miki Yokokawa; Aman Chugh; Anna Dubovoy; Milo Engoren; Krit Jongnarangsin; Rakesh Latchamsetty; Hamid Ghanbari; Mohammed Saeed; Ryan Cunnane; Thomas Crawford; Michael Ghannam; Jackson Liang; Robert Keast; David Karpenko; Frank Bogun; Frank Pelosi; Timur Dubovoy; Mathew Caldwell; Fred Morady; Hakan Oral
Journal:  J Cardiovasc Electrophysiol       Date:  2022-06-11       Impact factor: 2.942

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.